Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Comment by chipmuki1234567on Jun 02, 2014 3:47pm
386 Views
Post# 22622246

RE:Re: Seriously..

RE:Re: Seriously..Also there are a few other items most people leave out when they talk about this company. One is the stupid assumption that an approved FDA drug holds no value. It takes $mill to get a drug approved, so in a for sale scenario, that drug will be sold. Second, the need for equity financing at this stage - Given a low interest environment, do you think the company not pursue a debt financing first? Also, given they have an approved drug, do banks not want to loan this guys money? How about other big pharma's? lastly, on tefina, what do you think is the value of the drug. It increased the chance of orgasm from 1.7 to 2.3, with no side effects. If it gets approved, it will be hard not to, given the current scenario, how many women do you think will give this drug a try? think before you speak.
Bullboard Posts